Current status of leprosy: Epidemiology, basic science and clinical perspectives

Journal of Dermatology

Volumn 39, Issue 2, 2012, Pages 121-129

  Suzuki, Koichi ^a   Akama, Takeshi ^a   Kawashima, Akira ^a   Yoshihara, Aya ^a   Yotsu, Rie R ^b   Ishii, Norihisa ^a  

^a Laboratory of Molecular Diagnostics   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

diagnosis; disability; leprosy; Mycobacterium leprae; social stigma

Indexed keywords

CLARITHROMYCIN; CLOFAZIMINE; CORTICOSTEROID; DAPSONE; LEVOFLOXACIN; MINOCYCLINE; MONOCLONAL ANTIBODY; MOXIFLOXACIN; OFLOXACIN; RIFAMPICIN; SPARFLOXACIN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CLINICAL FEATURE; DIAGNOSTIC TEST; DISABILITY; DISEASE ACTIVITY; DISEASE TRANSMISSION; EDEMA; ERYTHEMA; ERYTHEMA NODOSUM LEPROSUM; GENOMICS; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LABORATORY TEST; LEPROSY; MEDICAL LITERATURE; MONITORING; MYCOBACTERIUM LEPRAE; NONHUMAN; PATHOLOGY; PREVALENCE; PREVENTIVE MEDICINE; REVIEW; STIGMA;

ANIMALS; DAPSONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEPROSTATIC AGENTS; LEPROSY; MALE; MYCOBACTERIUM LEPRAE; PERIPHERAL NERVOUS SYSTEM DISEASES; PREVALENCE; TREATMENT OUTCOME;

EID: 84863037383     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2011.01370.x     Document Type: Review

References (89)

1. WHO. Global leprosy situation, 2010. Wkly Epidemiol Rec 2010; 85: 337-348.
2. Saikawa K,. The effect of rapid socio-economic development on the frequency of leprosy in a population. Lepr Rev 1981; 52 (Suppl 1): 167-175. (Pubitemid 12172805)
3. Cole ST, Eiglmeier K, Parkhill J, et al. Massive gene decay in the leprosy bacillus. Nature 2001; 409: 1007-1011. (Pubitemid 32204045)
4. Brosch R, Gordon SV, Eiglmeier K, Garnier T, Cole ST,. Comparative genomics of the leprosy and tubercle bacilli. Res Microbiol 2000; 151: 135-142. (Pubitemid 30366700)
5. Harrison PM, Gerstein M,. Studying genomes through the aeons: protein families, pseudogenes and proteome evolution. J Mol Biol 2002; 318: 1155-1174. (Pubitemid 34753989)
6. Liu Y, Harrison PM, Kunin V, Gerstein M,. Comprehensive analysis of pseudogenes in prokaryotes: widespread gene decay and failure of putative horizontally transferred genes. Genome Biol 2004; 5: R64.
7. Nakata N, Matsuoka M, Kashiwabara Y, Okada N, Sasakawa C,. Nucleotide sequence of the Mycobacterium leprae katG region. J Bacteriol 1997; 179: 3053-3057. (Pubitemid 27194459)
8. Madan Babu M,. Did the loss of sigma factors initiate pseudogene accumulation in M. leprae? Trends Microbiol 2003; 11: 59-61.
9. Cole ST, Supply P, Honoré N,. Repetitive sequences in Mycobacterium leprae and their impact on genome plasticity. Lepr Rev 2001; 72: 449-461. (Pubitemid 34111839)
10. Lawrence JG, Hendrix RW, Casjens S,. Where are the pseudogenes in bacterial genomes? Trends Microbiol 2001; 9: 535-540. (Pubitemid 34121939)
11. Vissa VD, Brennan PJ,. The genome of Mycobacterium leprae: a minimal mycobacterial gene set. Genome Biol 2001; 2: REVIEWS1023.
12. Eiglmeier K, Parkhill J, Honore N, et al. The decaying genome of Mycobacterium leprae. Lepr Rev 2001; 72: 387-398. (Pubitemid 34111833)
13. Akama T, Suzuki K, Tanigawa K, et al. Whole-genome tiling array analysis of Mycobacterium leprae RNA reveals high expression of pseudogenes and noncoding regions. J Bacteriol 2009; 191: 3321-3327.
14. Akama T, Tanigawa K, Kawashima A, Wu H, Ishii N, Suzuki K,. Analysis of Mycobacterium leprae gene expression using DNA microarray. Microb Pathog 2010; 49: 181-185.
15. Nakamura K, Akama T, Bang PD, et al. Detection of RNA expression from pseudogenes and non-coding genomic regions of Mycobacterium leprae. Microb Pathog 2009; 47: 183-187.
16. Suzuki K, Nakata N, Bang PD, Ishii N, Makino M,. High-level expression of pseudogenes in Mycobacterium leprae. FEMS Microbiol Lett 2006; 259: 208-214. (Pubitemid 43828741)
17. Monot M, Honore N, Baliere C, et al. Are variable-number tandem repeats appropriate for genotyping Mycobacterium leprae? J Clin Microbiol 2008; 46: 2291-2297.
18. Monot M, Honore N, Garnier T, et al. On the origin of leprosy. Science 2005; 308: 1040-1042. (Pubitemid 40664418)
19. Monot M, Honore N, Garnier T, et al. Comparative genomic and phylogeographic analysis of Mycobacterium leprae. Nat Genet 2009; 41: 1282-1289.
20. Han XY, Seo YH, Sizer KC, et al. A new Mycobacterium species causing diffuse lepromatous leprosy. Am J Clin Pathol 2008; 130: 856-864.
21. Matsuo E,. Leprosy as a challenge to science on the ability to decode its enigma. A hypothesis on how to respond. Jpn J Infect Dis 2005; 58: 59-64. (Pubitemid 40754097)
22. Alford PL, Lee DR, Binhazim AA, Hubbard GB, Matherne CM,. Naturally acquired leprosy in two wild-born chimpanzees. Lab Anim Sci 1996; 46: 341-346.
23. Gormus BJ, Wolf RH, Baskin GB, et al. A second sooty mangabey monkey with naturally acquired leprosy: first reported possible monkey-to-monkey transmission. Int J Lepr Other Mycobact Dis 1988; 56: 61-65.
24. Hubbard GB, Lee DR, Eichberg JW,. Diseases and pathology of chimpanzees at the southwest foundation for biomedical research. Am J Primatol 1991; 24: 273-282.
25. Hubbard GB, Lee DR, Eichberg JW, Gormus BJ, Xu K, Meyers WM,. Spontaneous leprosy in a chimpanzee (Pan troglodytes). Vet Pathol 1991; 28: 546-548.
26. Leininger JR, Donham KJ, Meyers WM,. Leprosy in a chimpanzee. Postmortem lesions. Int J Lepr Other Mycobact Dis 1980; 48: 414-421. (Pubitemid 11139952)
27. Leininger JR, Donham KJ, Rubino MJ,. Leprosy in a chimpanzee. Morphology of the skin lesions and characterization of the organism. Vet Pathol 1978; 15: 339-346. (Pubitemid 8381880)
28. Meyers WM, Gormus BJ, Walsh GP, Baskin GB, Hubbard GB,. Naturally acquired and experimental leprosy in nonhuman primates. Am J Trop Med Hyg 1991; 44: 24-27.
29. Meyers WM, Walsh GP, Brown HL, et al. Leprosy in a mangabey monkey-naturally acquired infection. Int J Lepr Other Mycobact Dis 1985; 53: 1-14. (Pubitemid 15024462)
30. Suzuki K, Udono T, Fujisawa M, Tanigawa K, Idani G, Ishii N,. Infection during infancy and long incubation period of leprosy suggested in a case of a chimpanzee used for medical research. J Clin Microbiol 2010; 48: 3432-3434.
31. Truman R,. Leprosy in wild armadillos. Lepr Rev 2005; 76: 198-208. (Pubitemid 43168130)
32. Walsh GP, Meyers WM, Binford CH, Gerone PJ, Wolf RH, Leininger JR,. Leprosy-a zoonosis. Lepr Rev 1981; 52 (Suppl 1): 77-83.
33. Truman RW, Singh P, Sharma R, et al. Probable zoonotic leprosy in the southern United States. N Engl J Med 2011; 364: 1626-1633.
34. Davey TF, Rees RJ,. The nasal discharge in leprosy: clinical and bacteriological aspects. Lepr Rev 1974; 45: 121-134.
35. McDougall AC, Rees RJ, Weddell AG, Kanan MW,. The histopathology of lepromatous leprosy in the nose. J Pathol 1975; 115: 215-226.
36. Job CK, Jayakumar J, Kearney M, Gillis TP,. Transmission of leprosy: a study of skin and nasal secretions of household contacts of leprosy patients using PCR. Am J Trop Med Hyg 2008; 78: 518-521. (Pubitemid 351845207)
37. Krutzik SR, Ochoa MT, Sieling PA, et al. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat Med 2003; 9: 525-532. (Pubitemid 36597097)
38. Tanigawa K, Suzuki K, Kimura H, et al. Tryptophan aspartate-containing coat protein (CORO1A) suppresses Toll-like receptor signalling in Mycobacterium leprae infection. Clin Exp Immunol 2009; 156: 495-501.
39. Ferrari G, Langen H, Naito M, Pieters J,. A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell 1999; 97: 435-447. (Pubitemid 29231167)
40. Suzuki K, Takeshita F, Nakata N, Ishii N, Makino M,. Localization of CORO1A in the macrophages containing Mycobacterium leprae. Acta Histochem Cytochem 2006; 39: 107-112. (Pubitemid 44351510)
41. Barker LP,. Mycobacterium leprae interactions with the host cell: recent advances. Indian J Med Res 2006; 123: 748-759. (Pubitemid 44269941)
42. Chan J, Fujiwara T, Brennan P, et al. Microbial glycolipids: possible virulence factors that scavenge oxygen radicals. Proc Natl Acad Sci USA 1989; 86: 2453-2457. (Pubitemid 19102527)
43. Tanigawa K, Suzuki K, Nakamura K, et al. Expression of adipose differentiation-related protein (ADRP) and perilipin in macrophages infected with Mycobacterium leprae. FEMS Microbiol Lett 2008; 289: 72-79.
44. Mattos KA, Lara FA, Oliveira VG, et al. Modulation of lipid droplets by Mycobacterium leprae in Schwann cells: a putative mechanism for host lipid acquisition and bacterial survival in phagosomes. Cell Microbiol 2011; 13: 259-273.
45. Bleharski JR, Li H, Meinken C, et al. Use of genetic profiling in leprosy to discriminate clinical forms of the disease. Science 2003; 301: 1527-1530. (Pubitemid 37128543)
46. Mira MT, Alcais A, Nguyen VT, et al. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 2004; 427: 636-640. (Pubitemid 38248483)
47. Santos AR, Suffys PN, Vanderborght PR, et al. Role of tumor necrosis factor-alpha and interleukin-10 promoter gene polymorphisms in leprosy. J Infect Dis 2002; 186: 1687-1691. (Pubitemid 35379650)
48. Croft RP, Richardus JH, Nicholls PG, Smith WC,. Nerve function impairment in leprosy: design, methodology, and intake status of a prospective cohort study of 2664 new leprosy cases in Bangladesh (The Bangladesh Acute Nerve Damage Study). Lepr Rev 1999; 70: 140-159.
49. Mahajan PM, Jogaikar DG, Mehta JM,. A study of pure neuritic leprosy: clinical experience. Indian J Lepr 1996; 68: 137-141. (Pubitemid 26233687)
50. Suneetha S, Arunthathi S, Chandi S, Kurian N, Chacko CJ,. Histological studies in primary neuritic leprosy: changes in the apparently normal skin. Lepr Rev 1998; 69: 351-357. (Pubitemid 29022877)
51. Van Brakel WH, de Soldenhoff R, McDougall AC,. The allocation of leprosy patients into paucibacillary and multibacillary groups for multidrug therapy, taking into account the number of body areas affected by skin, or skin and nerve lesions. Lepr Rev 1992; 63: 231-246.
52. Ridley DS, Jopling WH,. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis 1966; 34: 255-273.
53. Ishikawa A, Ishikawa S, Hirakawa M,. Osteoporosis, bone turnover and hypogonadism in elderly men with treated leprosy. Lepr Rev 2001; 72: 322-329. (Pubitemid 33027135)
54. Boldsen JL,. Leprosy in the early medieval Lauchheim community. Am J Phys Anthropol 2008; 135: 301-310. (Pubitemid 351238539)
55. Boldsen JL, Mollerup L,. Outside St. Jorgen: leprosy in the medieval Danish city of Odense. Am J Phys Anthropol 2006; 130: 344-351. (Pubitemid 43855615)
56. Aufderheide AC, Rodríguez-Martín C,. The Cambridge Encyclopedia of Human Paleopathology. Cambridge University Press, Cambridge 1998.
57. Ortner DJ,. Identification of Pathological Conditions in Human Skeletal Remains, 2nd edn. Academic Press, London 2003.
58. Roberts C, Manchester K,. The Archaeology of Disease, 3rd edn. Cornell University Press, New York 2007.
59. Suzuki K, Takigawa W, Tanigawa K, et al. Detection of Mycobacterium leprae DNA from archaeological skeletal remains in Japan using whole genome amplification and polymerase chain reaction. PLoS ONE 2010; 5: e12422.
60. Courtright P, Daniel E, Sundarrao, et al. Eye disease in multibacillary leprosy patients at the time of their leprosy diagnosis: findings from the Longitudinal Study of Ocular Leprosy (LOSOL) in India, the Philippines and Ethiopia. Lepr Rev 2002; 73: 225-238.
61. WHO. Expert Committee on Leprosy. 7th report 1998: 1-13.
62. Report of the International Leprosy Association Technical Forum. Paris, France, 22-28 February 2002. Int J Lepr Other Mycobact Dis 2002; 70: S1-S62.
63. Sugita Y, Koseki M, Narita M, Kim S, Ishii N, Nakajima H,. Suitability of a skin-smear examination needle for leprosy screening by PCR. Int J Lepr Other Mycobact Dis 1992; 60: 658-659. (Pubitemid 23116995)
64. Buhrer-Sekula S,. PGL-I leprosy serology. Rev Soc Bras Med Trop 2008; 41 (Suppl 2): 3-5.
65. Kampirapap K,. Assessment of subclinical leprosy infection through the measurement of PGL-1 antibody levels in residents of a former leprosy colony in Thailand. Lepr Rev 2008; 79: 315-319.
66. Mwanatambwe M, Yajima M, Etuaful S, et al. Phenolic glycolipid-1 (PGL-1) in Buruli ulcer lesions. First demonstration by immuno-histochemistry. Int J Lepr Other Mycobact Dis 2002; 70: 201-205. (Pubitemid 35416721)
67. Burki T,. Old problems still mar fight against ancient disease. Lancet 2009; 373: 287-288.
68. Nicholls PG, Ross L, Smith WC,. Promoting early detection in leprosy-a literature review to identify proven and potential interventions addressing patient-related delay. Lepr Rev 2006; 77: 298-310. (Pubitemid 46423039)
69. WHO Technical Advisory Group on Leprosy Control. Report of the Tenth Meeting of the WHO Technical Advisory Group on Leprosy Control. World Health Organization Regional Office for South-East Asia, New Delhi 2009.
70. Kaimal S, Thappa DM,. Relapse in leprosy. Indian J Dermatol Venereol Leprol 2009; 75: 126-135.
71. Levy L, Moon N, Murray LP, O'Neill SM, Gustafson LE, Evans MJ,. Studies of the mouse foot pad technic for cultivation of Mycobacterium leprae. 1. Fate of inoculated organisms. Int J Lepr Other Mycobact Dis 1974; 42: 165-173.
72. Ishii N, Sugita Y, Sato I, Nakajima H,. Sparfloxacin in the treatment of leprosy patients. Int J Dermatol 1997; 36: 619-621. (Pubitemid 27386485)
73. Kai M, Matsuoka M, Nakata N, et al. Diaminodiphenylsulfone resistance of Mycobacterium leprae due to mutations in the dihydropteroate synthase gene. FEMS Microbiol Lett 1999; 177: 231-235. (Pubitemid 29352218)
74. Williams DL, Spring L, Harris E, Roche P, Gillis TP,. Dihydropteroate synthase of Mycobacterium leprae and dapsone resistance. Antimicrob Agents Chemother 2000; 44: 1530-1537. (Pubitemid 30340790)
75. Honore N, Cole ST,. Molecular basis of rifampin resistance in Mycobacterium leprae. Antimicrob Agents Chemother 1993; 37: 414-418. (Pubitemid 23072582)
76. Becx-Bleumink M, Berhe D,. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Int J Lepr Other Mycobact Dis 1992; 60: 173-184.
77. Kumar B, Dogra S, Kaur I,. Epidemiological characteristics of leprosy reactions: 15 years experience from north India. Int J Lepr Other Mycobact Dis 2004; 72: 125-133. (Pubitemid 39006885)
78. Scollard DM, Smith T, Bhoopat L, Theetranont C, Rangdaeng S, Morens DM,. Epidemiologic characteristics of leprosy reactions. Int J Lepr Other Mycobact Dis 1994; 62: 559-567.
79. Britton WJ,. The management of leprosy reversal reactions. Lepr Rev 1998; 69: 225-234. (Pubitemid 28484505)
80. Croft RP, Nicholls PG, Richardus JH, Smith WC,. Incidence rates of acute nerve function impairment in leprosy: a prospective cohort analysis after 24 months (The Bangladesh Acute Nerve Damage Study). Lepr Rev 2000; 71: 18-33. (Pubitemid 30237547)
81. Manandhar R, LeMaster JW, Roche PW,. Risk factors for erythema nodosum leprosum. Int J Lepr Other Mycobact Dis 1999; 67: 270-278. (Pubitemid 29536457)
82. Lockwood DN,. The management of erythema nodosum leprosum: current and future options. Lepr Rev 1996; 67: 253-259. (Pubitemid 27079678)
83. Jakeman P, Smith WC,. Thalidomide in leprosy reaction. Lancet 1994; 343: 432-433. (Pubitemid 24059581)
84. Moreira AL, Kaplan G, Villahermosa LG, et al. Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL. Int J Lepr Other Mycobact Dis 1998; 66: 61-65. (Pubitemid 28262090)
85. Senior K,. Stigma, chemoprophylaxis, and leprosy control. Lancet Infect Dis 2009; 9: 10.
86. Kazen RO,. Management of plantar ulcers in leprosy. Lepr Rev 1999; 70: 63-69. (Pubitemid 29221917)
87. Cross H, Newcombe L,. An intensive self care training programme reduces admissions for the treatment of plantar ulcers. Lepr Rev 2001; 72: 276-284. (Pubitemid 33027130)
88. Seboka G, Saunderson P, Currie H,. Footwear for farmers affected by leprosy. Lepr Rev 1998; 69: 182-183.
89. Nicholls PG,. Guidelines for social and economic rehabilitation. Lepr Rev 2000; 71: 422-465. (Pubitemid 32115028)